Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine

E. Bajetta, R. Buzzoni, S. Viviani, M. Vaglini, M. Nava, G. Bonadonna

Research output: Contribution to journalArticle

Abstract

Thrity-seven consecutive patients with disseminated malignant melanoma and previously untreated with chemotherapy were randomly allocated to receive vindesine, cis-platinum, and etoposide (Regimen A) or vindesine, cis-platinum, and lomustine (Regimen B). In 31 evaluable patients, Regimen A induced an overall response rate of 31% and a complete response rate of 6%; with Regimen B the corresponding findings were 20% and 20%, respectively. The median duration of complete response was 12 months with both regimens and the comparative median total survivals were 8 and 6 months, respectively. In no case was toxicity so severe to require treatment discontinuation, and the major dose-limiting side effect was myelosuppression, especially in the patients treated with Regimen B. Present results confirm once more the limited activity of drugs and regimens presently utilized in the treatment of advanced malignant melanoma.

Original languageEnglish
Pages (from-to)401-405
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume8
Issue number5
Publication statusPublished - 1985

Fingerprint

Vindesine
Lomustine
Etoposide
Cisplatin
Melanoma
Drug Therapy
Survival
Therapeutics
Pharmaceutical Preparations
Regimen B

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine. / Bajetta, E.; Buzzoni, R.; Viviani, S.; Vaglini, M.; Nava, M.; Bonadonna, G.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 8, No. 5, 1985, p. 401-405.

Research output: Contribution to journalArticle

@article{0ddabd753b6f460299e8f0fd37f76cce,
title = "Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine",
abstract = "Thrity-seven consecutive patients with disseminated malignant melanoma and previously untreated with chemotherapy were randomly allocated to receive vindesine, cis-platinum, and etoposide (Regimen A) or vindesine, cis-platinum, and lomustine (Regimen B). In 31 evaluable patients, Regimen A induced an overall response rate of 31{\%} and a complete response rate of 6{\%}; with Regimen B the corresponding findings were 20{\%} and 20{\%}, respectively. The median duration of complete response was 12 months with both regimens and the comparative median total survivals were 8 and 6 months, respectively. In no case was toxicity so severe to require treatment discontinuation, and the major dose-limiting side effect was myelosuppression, especially in the patients treated with Regimen B. Present results confirm once more the limited activity of drugs and regimens presently utilized in the treatment of advanced malignant melanoma.",
author = "E. Bajetta and R. Buzzoni and S. Viviani and M. Vaglini and M. Nava and G. Bonadonna",
year = "1985",
language = "English",
volume = "8",
pages = "401--405",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine

AU - Bajetta, E.

AU - Buzzoni, R.

AU - Viviani, S.

AU - Vaglini, M.

AU - Nava, M.

AU - Bonadonna, G.

PY - 1985

Y1 - 1985

N2 - Thrity-seven consecutive patients with disseminated malignant melanoma and previously untreated with chemotherapy were randomly allocated to receive vindesine, cis-platinum, and etoposide (Regimen A) or vindesine, cis-platinum, and lomustine (Regimen B). In 31 evaluable patients, Regimen A induced an overall response rate of 31% and a complete response rate of 6%; with Regimen B the corresponding findings were 20% and 20%, respectively. The median duration of complete response was 12 months with both regimens and the comparative median total survivals were 8 and 6 months, respectively. In no case was toxicity so severe to require treatment discontinuation, and the major dose-limiting side effect was myelosuppression, especially in the patients treated with Regimen B. Present results confirm once more the limited activity of drugs and regimens presently utilized in the treatment of advanced malignant melanoma.

AB - Thrity-seven consecutive patients with disseminated malignant melanoma and previously untreated with chemotherapy were randomly allocated to receive vindesine, cis-platinum, and etoposide (Regimen A) or vindesine, cis-platinum, and lomustine (Regimen B). In 31 evaluable patients, Regimen A induced an overall response rate of 31% and a complete response rate of 6%; with Regimen B the corresponding findings were 20% and 20%, respectively. The median duration of complete response was 12 months with both regimens and the comparative median total survivals were 8 and 6 months, respectively. In no case was toxicity so severe to require treatment discontinuation, and the major dose-limiting side effect was myelosuppression, especially in the patients treated with Regimen B. Present results confirm once more the limited activity of drugs and regimens presently utilized in the treatment of advanced malignant melanoma.

UR - http://www.scopus.com/inward/record.url?scp=0022406222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022406222&partnerID=8YFLogxK

M3 - Article

C2 - 3904398

AN - SCOPUS:0022406222

VL - 8

SP - 401

EP - 405

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 5

ER -